Table 1. Characteristics of the patients included in the study.

Patient code	Sex	Age	Histology	Stage	Number of CK+ CTCs	Clinical status at the moment of CTC collection
DX736	F	39	Breast adenocarcinoma	IV	0	Presentation
DX124	F	47	Breast carcinoma	IV	0	Stable disease to eribulin
DX755	M	56	Lung adenocarcinoma	III	0	Presurgery. After neoadjuvant therapy
DX753	F	69	Lung adenocarcinoma	IV	0	Major partial response to chemotherapy
DX138	F	47	Lung adenocarcinoma	IV	0	Progression to erlotinib (cerebellum)
DX288	M	68	Lung adenocarcinoma	IV	0	Complete response to erlotinib
DX295	M	69	Lung adenocarcinoma	IV	0	Major partial response to crizotinib
DX828	M	43	Lung adenocarcinoma	IV	0	Stable disease to chemotherapy
DX790	M	52	Small cell carcinoma	IV	0	Major partial response to chemotherapy
DX814	M	67	Small cell carcinoma	IV	0	Progression to chemotherapy
DX768	F	67	Squamous lung carcinoma	III	0	Partial response to chemotherapy
DX762	F	54	Squamous lung carcinoma	IV	0	Progression to chemotherapy
DX826	M	59	Tiroid anaplastic carcinoma	III	0	Postsurgery. No adjuvancy
DX785	F	58	Lung adenocarcinoma	IIA	1	Postsurgery. No adjuvancy
DX781	F	52	Lung adenocarcinoma	III	1	Postsurgery. No adjuvancy
DX839	M	66	Squamous lung carcinoma	IIB	1	Postsurgery. No adjuvancy
DX166	F	44	Breast carcinoma	III	2	Evaluation pending
DX516	F	48	Lung adenocarcinoma	IV	2	Stable disease to chemotherapy
DX743	M	74	Lung adenocarcinoma	IV	2	Progression to erlotinib
DX665	M	62	Lung adenocarcinoma	IV	2	Progression to chemotherapy
DX759	M	67	Small cell carcinoma	IV	2	Presentation
DX787	F	57	Small cell carcinoma	IV	2	Presentation
DX841	M	54	Prostate carcinoma	III	3	Presentation
DX568	M	45	Small cell carcinoma	IV	3	Progression to chemotherapy
DX776	M	41	Lung adenocarcinoma	I	4	Postsurgery. No adjuvancy
DX748	F	53	Squamous lung carcinoma	IV	4	Presentation
DX797	M	67	Lung adenocarcinoma	IV	5	Presentation
DX801	M	65	Lung adenocarcinoma	II	6	Postsurgery. No adjuvancy
DX783	M	50	Small cell carcinoma	IV	6	Presentation
DX792	M	49	Lung adenocarcinoma	IV	7	Progression to erlotinib